Local expression of transgene encoded TNF alpha in islets prevents autoimmune diabetes in nonobese diabetic (NOD) mice by preventing the development of auto-reactive islet-specific T cells by unknown
Local Expression of Transgene Encoded TNFcx in Islets 
Prevents Autoimmune  Diabetes in Nonobese 
Diabetic  (NOD)  Mice by Preventing the Development 
of Auto-reactive  Islet-specific T  Cells 
By Iqbal S. Grewal, Kate D. Grewal, E SusanWong, Dominic E. Picarella, 
Charles A. Janeway, Jr., and Richard A. Flavell 
From the Howard Hughes Medical b~stitute and Section of hnmunobiology, Yale University &hool of 
Medicine, New Haven,  Connecticut 06510 
Summary 
Lately, TNFoL has been the focus of studies of autoimmunity; its role in the progression of au- 
toimmune diabetes is, however, still unclear.  To analyze the effects of TNFoL in insulin-depen- 
dent diabetes mellitus  (IDDM),  we have generated nonobese diabetic  (NOD)  transgenic mice 
expressing TNFe¢ under the  control  of the  rat insulin  II promotor  (RIP).  In transgenic  mice, 
TNFot expression on the islets resulted in massive insulitis, composed ofCD4+  T  cells, CD8+ 
T  cells, and B  cells. Despite infiltration  of considerable  number of lymphoid cells in islets, ex- 
pression of TNFc¢ protected NOD  mice from IDDM. To determine the mechanism of TNFot 
action,  splenic  cells from control  NOD  and 1LIP-TNFc~ mice were  adoptively transferred  to 
NOD-SCID  recipients.  In contrast  to  the induction  of diabetes by splenic  cells from control 
NOD  mice, splenic cells from 1LIP-TNF(x transgenic  mice did not induce  diabetes m  NOD- 
SCID  recipients.  Diabetes  was  induced  however,  in  the  1LIP-TNFo~  transgenic  mice  when 
CD8+  diabetogenic  cloned T  cells or splenic cells from diabetic  NOD  mice were adoptively 
transferred  to  these  mice.  Furthermore,  expression  of TNFcx  in  islets  also  downregulated 
splenic  cell responses to autoantigens.  These  data establish a mechanism  of TNFcx action  and 
provide evidence that local expression of TN&x protects NOD  mice from autoimmune diabe- 
tes by preventing the development ofautoreactive islet-specific T  cells. 
I 
nsulin-dependent  diabetes  mellitus  (IDDM) 1 is  an  au- 
toimmune  disease  in  which  self-reactive  lymphocytes 
mediate the complete destructaon  of pancreatic  [3 cells (re- 
viewed  in  reference  1).  A  considerable  body  of evidence 
suggests that IDDM is determined by both genetic and en- 
vironmental  factors.  Of the  genes  involved,  the  strongest 
association between  IDDM is found between  genes of the 
major histocompatibility  complex  (MHC),  and specifically 
HLA-DQ  in humans  (2).  However,  a multitude  of studies 
show  that  IDDM  is  a  polygenic  disease  and  in  addition, 
studies with identical twins show a concordance  on the or- 
der of 30-50%, suggesting that environmental factors play a 
key role in the development of diabetes (3). 
The  study  of IDDM  has been  greatly facilitated  by the 
availability of good animal models  (4-7).  The Biobreeding 
(BB) rat and the nonobese diabetic  (NOD)  mouse develop 
a form of IDDM  that is broadly similar to the human  dis- 
ease.  The NOD  mouse has been the focus of considerable 
1Abbrevzat~ons used in ttus paper" BB, blobreeding; DLN, draining lymph 
nodes; GAD, glutamxc acid decarboxylase; IDDM, msuhn-dependent di- 
abetes mellitus; NOD, nonobese diabetic; PLN, perapheral lymph nodes; 
RIP, rat insulin II promotor. 
attention  since  it  shows  a  reproducibly  high  frequency  of 
&sease  (80-90%  of females  and  50-60%  in  males)  (4).  In 
the  NOD  mouse,  the  islets  of Langerhans  become  infil- 
trated with lymphoid cells, first around the islet (peri-insu- 
litis) around 3-4 wk, which gradually intensifies to insulitis. 
[3 cell destruction  follows and results in the loss of detect- 
able insulin and, the onset of overt diabetes, which plateaus 
at "-'4-6 mo of age. Genetic analysis shows that NOD  dia- 
betes is also a polygemc disease (8, 9). Of the genes involved 
in  diabetes,  the  MHC  (Idd-1),  plays  a  key  role  (10-12). 
Like  diabetes-susceptible  humans,  the  NOD  mouse  ex- 
presses an unusual  MHC  class II I-A allele (the mouse ho- 
mologue  of HLA-DQ),  which  carries  a  small  amino  acid 
residue  (S)  at  position  57;  this  parallel  structure  between 
these two susceptibility alleles has further supported the rel- 
evance of the  NOD  model to human  disease  (7,  13).  The 
use of modern genetic methods has led to the identification 
of other  recessive loci  which  predispose  to  IDDM.  Thus, 
genes  have been  identified  on chromosomes 3,  7,  11,  and 
14 which appear to play a cumulative role in increasing the 
frequency of IDDM.  Several of these genes, notably ldd-3 
and  Idd-10  on  chromosome  3,  predispose  to  insulitis  and 
diabetes, whereas Idd-5 seems to predispose predominantly 
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related,  there  are  certain  strains  of NOD  mice  such  as 
NOD/WEHI  which seem to show insulitis but little diabe- 
tes (15). These results  are broadly consistent with the concept 
that  insulitis  may be  necessary,  but  possibly  not  sufficient 
for the induction of diabetes.  However, the interpretation 
of these  kinds  of results  is  complex,  given  that  the  fre- 
quency  of diabetes  in  NOD  mice  is  notoriously variable 
from location to location,  and strongly influenced by nu- 
merous factors even including diet (4). 
A  considerable amount of data associates cytokines with 
the pathogenesis  of IDDM,  some of which is focussed on 
the cytotoxic effects ofcytokines on islet [3 cells (16-20). In 
contrast  to the  cytotoxic effects  of cytokines,  a protective 
role  of cytokines in  diabetes  in genetically diabetic  prone 
NOD  mice  and  BB  rats  has  also  been  postulated  (20). 
TNFc~ has been implicated in many pathological and phys- 
iological processes and has been the focus of many studies 
for past few years; its  role in exacerbation or protection of 
IDDM is however not clear. TNFo¢ is a potent inflammatory 
mediator which  activates  endothelial  cells  in  vitro  to  ex- 
press a number of leukocyte adhesion molecules, including 
E-selectin,  VCAM-1,  and  ICAM-1  (21).  It  also  strongly 
upregulates the level of MHC  class I on a variety of differ- 
ent  cell types,  including islets  (22).  Although TNFR  does 
not increase the level of MHC class II, it can synergize with 
IFN-y to cause upregulation of MHC class II on islets  (23). 
The proinflammatory properties  of TNFo~ in vitro  are re- 
flected in vivo. Thus, transgenic mice expressing TNF in a 
multitude  of tissues,  including  synovia  and  the  islets  of 
Langerhans, exhibit a pronounced infiltration of inflamma- 
tory  cells  (24-27).  In  fact,  detailed  studies  of transgenic 
mice in which the rat insulin promoter (RIP)  directed the 
synthesis of TNFoL or TNF[3 showed that these molecules 
direct the recruitment of CD4 and CD8 T  cells as well as 
B cells and cause upregulation of MHC class I but not MHC 
class  II  (25-27).  These  transgenic  mice  appear  to  express 
the transgene locally since circulating levels ofcytokines are 
not detectable,  and cultured islets  from transgene positive, 
but  not  from transgene  negative  mice,  express  significant 
levels  of TNFot.  Nonetheless,  the  infiltrate  induced  by 
TNFot does not lead to diabetes in these transgenic mice. 
Despite  the  proinflammatory  properties  of  TNFoL  in 
vitro and in vivo in transgenic animals, Jacob et al. showed, 
surprisingly, that TNFoL retarded the development of IDDM 
in adult NOD  mice, when administered  in pharmacologic 
doses (28). This striking result suggested that the inflamma- 
tory properties  of TNF~x  in fact have  an inhibitory rather 
than  a  stimulatory  effect  on diabetes  development.  How- 
ever,  the fact that this cytokine was presented  systemically 
confounds the interpretation of these studies. Specifically, it 
could be argued that the cytokines effects are distant rather 
than local at the islets of Langerhans, and could for example 
result in the recruitment  of leukocytes away from that tis- 
sue, because of the activation of endothelia elsewhere.  Sys- 
temic administration of cytokines can also act indirectly on 
the  immune system,  for example  IL-1 and TNFe~  can in- 
crease  the  secretion  of adrenocorticotropic  hormone  by 
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stimulating the hypothalamic-pituitary axis which suppresses 
inflammatory cells and cytokines (29). Alternatively, the ef- 
fects  of systemic  TNFo~  could  nonetheless  be  mediated 
through direct  events in the islets  of Langerhans.  In addi- 
tion,  a  recent  demonstration  of exacerbation  of develop- 
ment of diabetes,  when  TNFoL administered  early starting 
with neonatal NOD  mice, indicates the complex effects of 
TNFoL  on  IDDM  (30).  Results  showing  a  controversial 
role of TNFcx by pharmacological administration of TNFcx 
were further complicated by finding that when pharmaco- 
logic doses of monoclonal anti-TNFot antibodies were ad- 
ministered  for  4  wk,  the  incidence  of diabetes  in  NOD 
mice was significantly reduced.  On the  other hand,  when 
anti-TNFc~ antibodies  were administered  for a period of 8 
wk,  the  incidence  of diabetes  was  significantly  increased 
(31),  and  diabetes  were  completely prevented  when  anti- 
TNFot  monoclonal  antibodies  were  administered  neona- 
tally (30).  To address  the  effect of local TNFoL in islets  of 
NOD  mice  and  determine  the  mechanism  of action  of 
TNFoL in IDDM,  we generated  transgenic  mice in which 
the TNFot  gene was directed by the RIP and injected  di- 
rectly  into  NOD  mice.  To  our  surprise,  the  resulting 
NOD  mice  show  pronounced  resistance  to  spontaneous 
IDDM.  However,  they  remain  susceptible  to  adoptive 
transfer of IDDM with mature effector cells.  These results 
therefore  support  the  notion that locally produced  TNFot 
protects islets  from diabetes by inhibiting the development 
of auto-aggressive T  cells. 
Materials  and Methods 
Mice.  NOD mice ongmally obtained from Jackson Laborato- 
nes (Bar Harbor, ME) were bred in our colony. All mice used in 
this project were housed in specific pathogen-free conditions. In 
our colony, female  NOD mice develop diabetes  from 12 wk of 
age reaching 90% by 24 wk.  NOD-SCID mice were obtained 
from the Jackson Laboratories.  RIP-TNFc¢ transgenic  mice were 
generated by us, and both transgenic  positive and non-transgemc 
litter mates  were housed in specific pathogen-free condmons m 
our NOD colony. 
Generation of Transgenic Mice.  RIP-TNF<x transgenic mice were 
generated as described  previously (27). In brief,  the locus encod- 
ing murine  TNFe~ were  derived  from EMBL 7  clone  13  sub- 
cloned into pUC-12.  The TNFoL gene was isolated  as a 2.7-kb 
NarI/SaI  fragment  and  subcloned  into  ClaI/SalI  sites in  pSK- 
RIP. This construct was used previously to generate IKIP-TNFoL 
transgenlc  mice  in  (C57BL/B  X  CBA)F2  mice  (27);  in  these 
mice TNFo~ was faithfully expressed  under the control of RIP as 
reported  earlier  (27). For this  project transgenic  mice were  di- 
rectly  constructed  in  NOD  background  by injecting  femhzed 
NOD  eggs with  the  same  construct.  Several  transgene  posinve 
founder lines were established by screening mice for expression  of 
R.IP-TNFcx by Southern analysis of DNA extracted from tails. 
One of the founder hnes  (V 93.3)  was  crossed  with NOD and 
offsprings  were  monitored  for  IKIP-TNF<x  expression.  Both 
transgene  posmve and negative  progeny were housed under the 
same conditions and were monitored for the phenotyplc effects. 
Measurement of TNFoe Secretion by Islets.  Islets were  isolated 
by collagenase digestion  of whole pancreata.  100-150 islets were 
cultured  in  0.5  ml  of DMEM  containing 20  mM  glucose  and 
Transgene Encoded TNFoL m Islets 10% fetal calf serum for 24 h, as previously described (27).  Super- 
natants were  collected and analyzed for  presence  of TNFIx by 
ELISA methods. ELISA procedures were performed by using an- 
tibodies obtained from PharMingen (San Diego,  CA)  and their 
recommended protocols were followed. 
Immunohistochemistry and Assessment of lnsulitis.  Insulitis was  as- 
sessed by histology. Pancreata were prepared for histological anal- 
ysis by either immediate freezing of the tissue in OCT compound 
over dry ice or by fixing in 10% formalin and then embedding in 
paraffin as  described previously (26).  Paraffin  embedded blocks 
were  sectioned  and  stained  with  hematoxylin  and  eosin.  The 
shdes  were viewed by light microscopy for presence and pattern 
of msulitis. Frozen sections were prepared for evaluating presence 
of CD4 and CD8 T  cells,  B  cells and macrophages in islet infil- 
trates.  Monoclonal antibodies  (conjugated  with  biotin)  against 
CD4, CDS, macrophage(F/480) and B220 markers were used to 
stain frozen sections and slides  were developed and processed as 
described previously (26). 
Diabetes Measurements.  Diabetes was assessed by weekly mea- 
surement of unne glucose by using Dlastix (Ames, Elkhart,  IN), 
and  diabetes  was  confirmed  by  blood  glucose  measurements. 
Mice were  considered to  be diabetic if three  consecutive mea- 
surements of blood glucose were greater than 250 g/dl. To elim- 
inate possible artifacts  caused by environmental components such 
as  food,  transgene  positive  and  transgene  negative  mice  were 
housed  together;  we  reasoned  that  any  artefact  of this  nature 
would be localized to individual cages,  and therefore would ran- 
domize across transgene positive and transgene negative mice. 
Flow CytometricAnalysis.  Single  cell  suspensions  of  spleen, 
peripheral lymph nodes, blood, and thymus tissue were prepared 
from  6-8-wk-old NOD  or  RIP-TNFci  transgenic mice.  Cells 
were stained by incubating for 45 mm at 4°C with ant-CD4-PE, 
antl-CD8-FITC, and B220-Biotin. Cells were subsequently washed 
and fixed in 1% formaldehyde. Samples were analyzed on a Bec- 
ton Dickinson FACS  ® star plus Flowcytometer. A  minimum of 
10,000 cells were collected for each sample. 
Leukocyte Isolation and Counts.  Single  cell  suspensions  from 
spleen,  thymus,  penpheral  lymph  nodes  (cervical,  axillary,  in- 
guinal, and periaortic),  and mesentenc lymph nodes were  pre- 
pared and the number of cells were determined using a hemocy- 
tometer. Blood samples were  obtained by puncture of the retro 
orbital plexus of anesthetized mice. 
T Cell Proliferation Assay.  For polyclonal stimulation of T  cells, 
5  ×  105  splenic  cells  were  cultured in presence  of 2.5  Ixg/ml 
ConA or 3  p~g/ml antl-CD3 in 96-well plates in Bruffs medium 
supplemented with 5% FCS, 2  mM glutamine, 100  U/ml peni- 
cflhn,  100  p,g/ml streptomycin, and different concentrations of 
the antigen. Proliferation was measured by addition of 1 p~Ci of 
[3H]thymidine (International Chemical and Nuclear, Irvine, CA) 
for the last  18 h ofa 5-d culture, and incorporation of radioactiv- 
ity was assayed by liqmd scintillation counting. For anti-KLH re- 
sponses, mice were lmmumzed with 100 p~g KLH in a 1:1 emul- 
sion  with  CFA,  containing  1  mg/ml  Mycobacterium tuberculosis 
strain H37Ra, (Difco Laboratories, Detroit, MI) in the hind foot- 
pads. After 9 d, the popliteal lymph nodes were removed and cell 
suspensions were prepared.  The lymph node cells were  cultured 
(5 ×  10  s per well) in various concentration of KLH in bruffs me- 
chum supplemented with 5% FCS. Proliferanon was measured by 
uptake of [3H]thymidine as stated above. 
T  Cell Proliferation in Response to Islet Extracts and  GADp524- 
543.  Spleen  cell  proliferation  in  response  to  islet  extracts  or 
GADp524-543 (SRLSKVAPVIKARMMEYGTT) were  measured 
by  cultunng spleen  cells  (1  ×  106/well)  obtained  from  R.IP- 
TNFot  transgenic  or  non-transgenic mice  in  HL-1  serum-free 
medium as described (32).  Islet cell extracts were prepared by iso- 
lating islets by collagenase digestion of whole pancreata, as previ- 
ously described (27) followed by sonication of single cell prepara- 
tion of islets and five cycles of freeze thaw. Proliferation of spleen 
cells was measured in 5-d culture by uptake of [3H]thymidine as 
mentioned above. 
Cytokine Assays.  Assays  for  cytokine  production  by  spleen 
cells  from  RIP-TNFo~ transgenic or non-transgenic mice were 
done by culturing 1 ×  10 s purified CD4+  T  cells with 5  X  105 
irradiated (3,000 R) splenic cells from unlmmumzed NOD mice 
and different amounts of the  GADp524-543 in Bruffs medium, 
supplemented as described above. After 24 h of culture, 100 ~1 of 
culture supernatant was removed from each well for IL-2 mea- 
surements. For IL-4 and IFN~/measurements, supernatants were 
removed after 4 d  of culture. ELISA method was used to deter- 
mine  cyto~ne  levels  in  supernatants,  using  antibodies  from 
PharMingen, and using their recommended protocols. 
Anti-GADp524-543 Antibodies Analysis by ELISA.  Anti-GAD- 
p524-543  levels  were  determined by  specific  ELISA  method. 
Briefly,  96-well plates were  coated with  10  ~xg/ml GADp524- 
543 for 24 h. Plates were then washed and blocked with 1% FCS 
in PBS. Diluted serum samples were then added to triplicate wells 
and plates were  incubated for  1 h  at 37°C. Plates were  washed 
and the antigen specific antibody titers determined with the bi- 
otin conjugated goat anti-mouse-Ig detection antibody (South- 
ern Biotechnology, Birmingham, AL). ELISA was developed by 
using streptavidm  conjugated horse  radish peroxidase  and Elisa 
T-Turbo developing reagent substrate  (ICN  Biomedlcals,  Inc., 
Costa Mesa,  CA).  Plates were analyzed on a Dynatech MR700 
ELISA plate reader (Dynatech Labs., Inc., Chantilly, VA). 
Generation and Propagation of CD8 Diabetogenic T  Cell  Clones. 
The CD8 diabetogemc T  cell clones used in this project are well 
characterized (33) and cause rapid diabetes upon adoptive transfer 
to NOD-SCID mice. These clones were generated from islet m- 
filtrates of 7-wk-old females as described by us previously, and 
were routinely maintained by our laboratory (33). 
Adoptive  Transfer of Diabetes.  Adult female RIP-TNFo~ trans- 
genic and non-transgenic litter mates and NOD-SCID mice were 
used as recipients. In some experiments, recipient mice were irra- 
diated with 725 rad from a caesium source. Spleen cells from dia- 
betic NOD or non-diabetic NOD or from RIP-TNFot mice (6- 
10  ×  106  cells/mouse )  or  CD8  cloned T  cells 6  ×  106  were 
adoptively transferred intravenously to recipient mice. Non-irra- 
diated recipients were  examined for diabetes on a weekly basis 
and irradiated recipient mice were  monitored for diabetes daily 
after adoptive transfer. 
Results 
Generation  of Transgenic NOD  Mice Expressing  RIP-TNFa. 
We used the same construct that we have described previ- 
ously  that  directs  the  expression  of  substantial  levels  of 
TNFct in (C57BL/6  ×  CBA)F2 mice (27). In our previous 
study  we  constructed  several  lines  of transgenic  mice  in 
which  the  expression  of this  gene  showed  reproducible 
production of TNFot from the pancreas but not from other 
tissues  tested.  Specifically,  this  transgene  was  expressed  at 
the level of RNA  and protein in pancreatic  tissue,  and as 
biologically active TNFo~ in supernatants from cultured is- 
lets.  In situ hybridization in those  studies showed  that  the 
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Figure  1.  Production  of 
TNF(x by islets from 1LIP-TNFc¢ 
transgemc mace. Islets from RIP- 
TNF(x transgemc mace (R)  or 
from negative  litter mate control 
NOD  mace (~1) ranging  m age 
from 4 wk to 13 wk were exam- 
reed for TNF(x secretion. Islets 
pooled from four mice were cul- 
tured for 48 h in 0.5 ml of cul- 
ture medium contamlng 20 mM 
glucose. Amount of TNF(x se- 
creted in supematants at a dilu- 
tion of 1:10 were determined by 
TNFc~-speclfic  ELISA. 
TNFo~ expression in the islets was localized to the islets and 
not to the infiltrating mononuclear cells which developed 
in these animals. Fertilized NOD  eggs were injected with 
this  validated  construct,  and  several  transgene  positive 
founder  lines  were  obtained.  Transgene  founders  were 
crossed with NOD  mice and their progeny was examined 
for expression of RIP-TNFe¢ by Southern analysis (27). Af- 
ter preliminary characterization, line V  93.3  was  selected 
and further bred with NOD  mice to monitor the pheno- 
typic effects.  Expression of TNF(x protein by islets was de- 
termined by analyzing supernatants from cultures contain- 
ing islets from transgene positive or negative litter mates in 
the presence of glucose. A  considerable amount of TNFot 
was secreted by islets obtained from RIP-TNFot transgenic 
mice  after  48  h  of culture,  whereas  no  TNFot was  pro- 
duced by the islets of control mice cultured under similar 
conditions (Fig. 1). These results indicate that TNFct is ex- 
pressed and secreted by islets oftransgene positive mice. To 
determine  at  what  age  TNFo~  is  first  expressed  in RIP- 
TNF(x mice, islets obtained from mice of various ages were 
tested for production of TNFot in vitro. TNFa  could not 
be  detected  in  mice  of 4  wk  old,  whereas  measurable 
amounts of TNFot was detected at 7 wk of age and at later 
time points  (Fig.  1).  In addition, serum from these  mice 
was  also  tested  to  determine levels of TNF(x.  No  TNFo~ 
could be detected in serum of transgenic mice at any age 
(data not shown). This result indicates that TNF(x is only 
locally expressed in islets of Langherhans. 
Expression of TNFe¢ in the Pancreas of Transgenic NOD Mice 
Results in Insulitis.  Our previous studies indicated that the 
RIP-TNFoL transgene mediates dramatic infiltration of lym- 
phocytes in the islets of Langerhans in mice generated on 
the (C57BL/6  ×  CBA)F2 background that had been back 
crossed to C57BL/6 (27). We therefore monitored the ef- 
fects of RIP-TNFot transgene on insulitis as a function of 
age in NOD  mice.  Histological examination of pancreata 
from 1LIP-TNFoL transgenic mice reveals that mononuclear 
PrevenUon of Diabetes by Transgene Encoded 
Figure 2.  Histologacal  analysis  of insuhtis m RIP- 
TNF(x transgenic mice. Paraffin-embedded  pancreas 
sections  from RIP-TNF~  transgenic mice were 
stained with hematoxyhn and eosm ranging in age 
from 4 wk to 48 wk; (A) 4 wk old, (B) 7 wk old, (C) 
9 wk old, (D) 13 wk old, (E) 26 wk old, and (/:) 48 
wk old. Umque patterns of lnsuhtis  was discovered m 
islets of KIP-TNFeL  mice. 
1966  TNFa in Islets Figure  3.  Insuhn and  glucagon staining of pancreas 
from tklP-TNFot transgemc mace (A and C) and negative 
transgenic htter mate control mice (B and D). Paraffin- 
embedded sections were stained with antibodies against 
msuhn (A and B) and with glucagon (C and D). 
cells begin to infiltrate  into islets  at ~7  wk old. This infil- 
tration  (insulitis)  was restricted  to islets  and it was not ob- 
served in surrounding acinar tissues  (Fig.  2).  In contrast to 
non-transgenic  NOD  mice,  the  immune  cell  infiltrate  in 
1LIP-TNFc~ transgenic  mice progresses to massive infiltra- 
tion,  almost completely obscuring the islets.  The nature of 
the infiltrating cells was determined by immunohistochem- 
ical  staining  of frozen  pancreata.  Immunohistochemical 
staining  shows  the  presence  of numerous  CD4  and  CD8 
cells  as well as B220+  cells in the infiltrates  of RIP-TNFoL 
transgenic mice (data not shown). 
Infiltration  of Mononuclear  Cells  into  Islets  in  RIP-TNFa 
Transgenic Mice Does Not Prevent Insulin Production.  To  as- 
certain  whether  the  massive  infiltration  of mononuclear 
cells  in islets  of RIP-TNFc~ transgenic  mice  affects  func- 
tioning of the beta cells in RIP-TNFa  transgenic mice, we 
analyzed  paraffin  embedded  sections  of  pancreata  from 
1<IP-TNFc~ mice for insulin and glucagon by immunocy- 
tochemistry (Fig. 3). Examination of the sections from con- 
trol NOD  mice showed the presence of glucagon-produc- 
ing cx cells aligned along the perimeter of the islet capsule, 
and considerable damage to insulin-producing 13 cells  were 
predominantly in the central portion of the islet, indicating 
normal organization of e¢ and 13 cells in these sections.  By 
contrast,  sections  from  RIP-TNFot  transgenic  mice  re- 
vealed no damage to 13 cells  or loss of insulin content in is- 
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lets;  however the  organization of the  glucagon producing 
cells was disrupted (with ot cells located within islets)  as we 
described  previously  for  the  tLIP-TNFot  transgenic  mice 
on  the  B6  background  (27).  Thus,  in  spite  of massive 
mononuclear infiltration of islets  in P,  IP-TNFc~ mice, their 
13 cell physiology remains normal. 
Expression  of TNFo~  in  Islets  Prevents  the  Development  of 
Spontaneous Diabetes  in NOD Mice.  RIP-TNFoL transgene 
positive and non-transgenic litter mates were then housed 
under  the  specific  pathogen-free  conditions  used  for  our 
NOD  colony and monitored for the  development  of dia- 
betes.  Since female mice develop diabetes at a significantly 
greater  frequency  than  male  NOD  mice,  we  monitored 
only females in  this  study.  Expression  of TNF-ot  in islets 
dramatically retarded the development of IDDM. Whereas 
~80% of female NOD  transgene-negative mice developed 
diabetes  by 25  wk,  at  this  time  only ~'-,15% of transgene 
positive  animals  developed  disease.  This  study  was  per- 
formed with two separate groups of animals, both of which 
are summarized in Fig. 4. Thus, whereas transgenic TNFot 
mediated  substantial  infiltration  into  the  islets  of Langer- 
hans, this did not lead to autoimmune diabetes. 
Expression of TNFa in the Pancreas of Transgenic NOD Mice 
Has No Effects on the Number of Lymphocytes in Lymphoid Or- 
gans or on In Vitro Proliferation of T  Cells.  To rule  out the in- 
fluence of TNFot expression in islets  on lymphocyte devel- 100- 
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Figure 4.  Onset of &abetes in P,  IP-TNFoL mice  Transgene posztlve 
mice (0) and negative litter mates (~) were housed randomly (both posi- 
tive [n = 28] and negative [n = 37] mice in the same cages) m filter frame 
units. Diabetes was measured by monltonng of urinary glucose followed 
by blood glucose. Mace were considered to be diabetic if three consecu- 
tive measurements of  blood glucose  greater than 250 mg/dl were observed. 
that the protection offered by the RIP  encoded transgene 
(TNFo  0  may be due to general suppression of the immune 
system.  To  rule  out  this  possibility, we  used  an  antigen- 
specific system to measure  T  cell responses of RIP-TNFei 
transgenic mice to a well-characterized foreign protein an- 
tigen, keyhole limpet hemocyanin (KLH). Mice were im- 
munized with KLH in complete Freund's adjuvant (CFA) 
and  9  d  later  their  draining  lymph  nodes  (DLN)  were 
tested for in vitro recall proliferative responses. RIP-TNFci 
transgenic mice exhibited recall prohferative responses sim- 
ilar to that ofnon-transgenic litter mates, indicating that lo- 
cal expression of TNFot in islets does not lead to the induc- 
tion of suppression of immune responses to foreign protein 
antigens (Fig. 6). Thus, these data suggest that expression of 
TNFot  in  islets does  not  cause  general suppression  of the 
immune system. 
Expression  of TNFce in Islets Inhibits the Development of Im- 
mune Responses to Islets and GAD Peptide.  Although the stud- 
ies presented above show that responses to foreign protein 
antigens  in  RIP-TNFcl  transgenic  mice  are  not  signifi- 
cantly different from negative litter mate controls, the pos- 
sibihty that  specific regulatory mechanisms  could suppress 
islet specific autoimmune  responses remained an  explana- 
tion  for  suppression  of IDDM  by IklP-TNFot transgene. 
To  address  this  we  examined  the  spontaneous  T  cell re- 
sponses  and  serum  antibody levels to  a  synthetic peptide 
derived from glutamic acid decarboxylase (GAD), contain- 
ing amino acid sequence 524-543  (GADp524-543).  Spon- 
taneous immune responses to this peptide in young NOD 
mice  has  been  shown  previously  (32).  To  determine 
whether  spontaneous  responses  to  GADp524-543  are m- 
hibited by local expression of TNFoL in islets, splenic cells 
from  both  1LIP-TNFot  and  non-transgenic  litter  mates 
were  examined for proliferation and  cytokine production 
in response to in vitro challenge with this peptide. Splenic 
cells  from  RIP-TNFcx  mice  showed  a  complete  lack  of 
proliferative responses to GADp524-543, whereas a signifi- 
opment, we carefully examined the various subpopulations 
oflymphocytes in lymphoid organs in P,  IP-TNFot transgenic 
mice. Both R.IP-TNF~x transgenic and non-transgenic mice 
were  examined for the number  and ratios of CD4,  CD8, 
and B220  positive cells in spleen, peripheral lymph nodes 
(PLN),  thymus  and  blood  by  Flow  cytometry.  The  fre- 
quency  of various  subsets  of lymphocytes in  RIP-TNFo~ 
and non-transgenic litter mates were indistinguishable, in- 
dicating that local expression of TNFc~ in islets does not in- 
fluence the development of lymphoid tissues in NOD  mice 
(Fig. 5). In addition, in vitro proliferative responses of PLN 
cells to CD3  and ConA were measured, and the data pre- 
sented in Table  1  indicates that  in vitro T  cell prolifera- 
tion in response to polyclonal stimulators is normal in RIP- 
TNFoL transgenic mice. 
Expression  of TNFa in the Pancreas of Transgenic NOD Mice 
Does Not Induce  Generalized Immunosuppression.  Since  ex- 
pressrun  of TNFot  in  islets prevents  the  development  of 
spontaneous  diabetes in transgenic mice,  one  could argue 
Table 1.  In Vitro Proliferation of Naive T Cells in the Presence 
of PolyclonaI Stimuli 
Spleen cell proliferation 
Con-A (Ixg/ml)  otCD3 (Ixg/ml) 
0.01  0.1  2.0  5.0  0.1  1.0  5.0  10.0 
Stimulation index 
NOD  4.03  5.99  10.18  16.03  3.4  5.17  10.40  14.53 
RIP-TNF  4.67  6.68  15.89  27.73  4.33  7.35  15.54  18.78 
Lymph  node  T  cells purified  from  unimmunized  RIP-TNFa trans- 
genlc mice or negative transgemc litter mates were cultured in the pres- 
ence of media alone or anti-CD3 (A) and ConA. Prohferatlon was de- 
termined after 4 d of culture  by incorporation  of [3H]thyrmdme and 
data are presented as stimulation index. 
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Figure 5.  Flocytometry analysis of various subpopulatmns of lymphocytes an lymphoid organs  Both RIP-TNFot transgenic m~ce and negative litter 
mates were examined for CD4, CD8, and B220 expressing cells in spleen, lymph node, blood, and thymus by stamlng them with monoctonal antibo&es 
agamst these markers. Values given in the quadrants are the percent events withm that quadrant. Values given in histograms are percent gated events in- 
dicated by a bar. 
cant response  was apparent  in  the spleen  of non-transgenic 
litter  mates  (Fig.  7  A).  Splenic  ceils  from  non-transgenic 
NOD  mice,  showed  significant  production  of IL-2,  IL-4, 
and  IFNy,  whereas  no  such production  of cytokines  could 
be  detected  from  spleen  cells  from  R.IP-TNFot  transgenic 
mice  (Fig.  7,  B-D).  In  addition,  serum  from  both  non- 
transgenic  and 1KIP-TNFoc  transgenic  mice were  tested for 
the  presence  of anti-GAD  antibodies.  The  levels  of anti- 
GADp524-543  antibodies  were  significandy  lower  in  RIP- 
TNFot  transgenic  mice when  compared with non-transgenic 
litter mates  (Fig.  7  e).  In addition,  proliferative  responses  of 
splenic  cells  from  1KIP-TNFot  and  non  transgenic  litter 
mates  were  measured  against  islet  extracts  obtained  from 
NOD  mice  or  from  1KIP-TNFc~  transgenic  mice.  Again  a 
lack of proliferative  response was seen in 1KIP-TNFot trans- 
genic  mice,  whereas  non  transgenic  mice  responded  well 
(Fig.  7  a).  These  results  demonstrated  that local expression 
of TNF~x  had  profound  effect  on  the  development  of au- 
toantigen  specific  immune  responses  in  both  the  B  and 
T  cell  compartments.  Moreover,  since  splenic  cells  from 
0  i  ! 
0.0,  011  ,  ~  ,00 
KLH  ~tglrnl 
non transgenic  mice were  able to proliferate  in response  to 
islets  from  RIP-TNFct  transgenic  mice,  it  can  be  con- 
cluded  that  expression  of TNFot  does  not change the  anti- 
genic moieties present on or in the islets. 
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Figure  6.  Recall  prohferatxve 
responses of KLH-prlmed dram- 
mg  lymph  node  cells. In  vitro 
prollferatwe  recall  responses  of 
RIP-TNFot transgemc mace (O) 
and  negative litter mate control 
mice  (m)  to  KLH.  Draining 
lymph node cells from mine im- 
munized with KLH/CFA 9 days 
earher were cultured m the pres- 
ence of media alone or indicated 
concentranons of KLH. Prohfer- 
anon  was  determined after 4  d 
of  culture  by  incorporation  of 
[3H]thymldme and data are pre- 
sented as stlmulanon index. A 
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Figure 7.  In vitro prohferatlon of nmve T cells in presence of various 
antigens T cells purified  from ummmunlzed  P,.IP-TNF(x  transgenic  mice 
(open bars) or negative transgenic  litter mates (filled bars) were cultured in 
the presence of media alone or indicated antigens (A). Prohferatlon was 
determined after 4 days of culture by incorporation  of [3H]thyrmdlne  and 
data are presented as stlmulanon index. Cytokme production by T cells 
purified from spleens of ummmumzed lq.IP-TNF(x transgenic  rmce (0) 
or negative transgenlc  litter mates (ml) cultured in the presence of media 
alone or GADp524-543, IL-2 production (B), IL-4 production (C), and 
IFNy  production  (D). (E)  Presence  of  serum antibodies  against 
GADp524-543 in P,.IP-TNFot  transgenlc  rmce (0) or neganve transgenlc 
litter mates (I) from individual  mice as determaned  by ELISA. 
Table  2.  Transfer  of Diabetes by Adoptive  Transfer of Sple,,ic Cells 
Adoptively  Transferred Splenic Cells from RIP-TNFa  Trans- 
genic Mice Fail to Cause Diabetes in NOD-SCID Mice.  To  un- 
derstand the mechanism of protection offered by local ex- 
pression of TNF(x in islets, we adoptively transferred splenic 
cells from diabetic NOD  mice or from age matched RIP- 
TNFo~  transgenic mice  to  NOD-SCID  recipients. When 
diabenc splenic cells from NOD mice were transferred into 
NOD-SCID recipients, diabetes developed within 2-3 wk, 
whereas  age  matched splenic cells from P,.IP-TNFot mice 
failed to cause diabetes in NOD-SCID recipients (Table 2). 
We also adoptively transferred splenic cells from age matched 
non-diabetic, non-transgenic mice  to  NOD-SCID  mice, 
and again diabetes developed in recipient mice, although, 
the  development of diabetes was slower than that induced 
by splenic cells from diabetic NOD mxce.  These results sug- 
gest that sensitized autoreactive T  cells having the potential 
to cause diabetes were present in the spleens of NOD mice 
while  the  splenic cell population from P,.IP-TNFot trans- 
genic  mice  lacked  this  capabihty.  The  inability of spleen 
cells from R.IP-TNFot transgenic mice to cause diabetes in 
NOD-SCID  recipients on adoptive transfer could be  ex- 
plained at least by two possible mechanisms: either autore- 
active cells with the potential to  cause diabetes fail to  de- 
velop in RIP-TNFo~ transgenic mice, or autoreactive cells 
are  present in the  spleens of P,.IP-TNF(x transgenic mice 
but these cells are prevented from attack in the islets of the 
recipient mice by some kind of regulatory mechanism. In 
addition, these results also suggested that TNFo~ expression 
in islets is not required to protect islets from a destructive 
immune response. 
To  distinguish these  possibilities, we  adoptively trans- 
ferred a mixture of diabetic spleen cells and spleen cells ob- 
tained from P,  IP-TNFot mice  to  NOD-SCID  recipients, 
and  examined  the  development  of diabetes  in  recipient 
mice.  Admixture of spleen cells from  diabetic mice  with 
spleen cells from R.IP-TNFo~ mice did not prevent the de- 
velopment of diabetes (Table 2), but delayed the develop- 
ment of diabetes by a few weeks. Although these results in- 
dicate that protection offered by local expression of TNF(x 
is not due to generation of potent specific regulatory sup- 
pressor cells, we cannot rule out the possibility of such reg- 
ulation by these  simple adoptive transfer experiments. To 
Source of Cells  Recipients  3  4 
Incidence of diabetes (weeks post-transfer) 
5  6  7  8  9  10  11  12  13  14  23  40 
NOD (diabenc)  SCID 
NOD (Non-diabetic)  SCID 
RIP-TNFo~  SCID 
RIP-TNF(x +  NOD (diabetic)  SCID 
NOD (Non-diabetic) +  NOD (diabetic)  SCID 
3/6  5/6  6/6 
1/5  1/5  1/5  1/5  1/5  2/5  2/5  3/5  3/5  3/5  4/5  4/5  5/5 
0/9  0/9  0/9  0/9  0/9  0/9  0/9  0/9  0/9  0/9  1/9  1/9  1/9  1/9 
2/10  2/10  4/10  8/10  8/10  8/10  9/10  10/10 
2/4  4/4 
6--10 X 10  6 splenic cells depleted of Pd3C form NOD (diabetic within two weeks) mice were transferred intravenously either alone or in the pres- 
ence of the same amount ofsplemc cells from P.IP-TNF(x transgenic trace. Diabetes were monitored by urine glucose analysis  at weekly intervals. 
1970  Prevention of Diabetes by Transgene Encoded TNF(x in Islets Table 3.  Transfer  of Diabetes by Adoptive Transfer of CD8 +  Cells into Irradiated Recipients 
Incidence of diabetes  (days post-transfer) 
Source of Cells  Recipients  5  6  7  8  9  10  15  16  19  20 
NOD (diabetic)  NOD  0/3  0/3  0/3  0/3  0/3  0/3  0/3  1/3  2/3 
G9-C8  NOD  1/4  1/4  3/4  3/4  4/4 
NOD (diabetic)  RIP-TNFa  0/3  0/3  0/3  0/3  0/3  0/3  1/3  2/3  3/3 
G9-C8  RIP-TNFo~  1/4  3/4  4/4 
3/3 
6 ×  106 dxabetogemc cloned CD8+ T cells (G9-C8) or 10 ×  106 splemc cells depleted RBC form NOD (diabenc wxthin two weeks) rmce were 
transferred intravenously to lrra&ated (725 Rads) ILIP-TNFc~ transgenic mice or negative htter mates. Diabetes was monitored by urine glucose 
analysxs at daffy intervals. 
rule  out the  existence  of specific regulatory  cell mediated 
mechanism of protection by TNFci, further studies includ- 
ing  a  detailed  kinetics  analysis  by  using  various  ratios  of 
cells will be needed. 
Local Expression  of TNFa Does Not Protect Islets against Ef- 
fector Cells.  To  determine  if protection  offered  by  local 
expression of  TNFo~ in islets was mediated by the direct effects 
of TNFo¢ on the  functioning of effector cells,  we used an 
adoptive transfer system in which spleen cells from diabetic 
NOD  mice, or cloned diabetogenic CD8 T  cells (33) were 
used  to  transfer  diabetes.  Irradiated  NOD  or PdP-TNF0~ 
transgenic NOD  mice were adoptively transferred with ei- 
ther cloned CD8 T  cells or with diabetic splenic cells,  and 
the  development  of diabetes  was monitored  (Table  3).  In 
addition,  non-irradiated  recipients  were  also  adoptively 
transferred  with  cloned  CD8  T  cells.  Rapid  development 
of diabetes occurred in all cases,  indicating that TNFci does 
not block the functions  of effector cells  which are already 
primed in vivo (Table 4). 
Discussion 
Since  TNFo~  is  a  powerful  mediator  of inflammation 
with a pleiotropic range of actions, it is not surprising that 
this molecule has been found to be involved in autoimmu- 
nity. It is therefore of considerable interest that a few years 
ago Jacob et al.  (28) and Satoh et al.  (34) demonstrated that 
TNFIx, when administered in pharmacologic doses to adult 
NOD  mice and BB rats (35)  completely prevented the de- 
velopment of IDDM. However, the molecular and cellular 
basis  for  protection  offered  by  TNF~x  has  not  been  ex- 
plained.  Recently, Yang et al.  have shown that this  situa- 
tion is more complex, since administration  of TNFc~ neo- 
natally exacerbates the development of diabetes (30). These 
studies  implied  that  when  TNFo~ is  administrated  early it 
potentiates the initiating events in the development oflDDM, 
but if administered late,  it inhibits  an effector phase of the 
disease which normally leads to destruction of islets.  How- 
ever,  from the  above studies  it was not clear whether the 
effects of the systemic administration of TNFo~ were funda- 
mentally  pharmacologic  in  activity  and  regulated  the  au- 
toimmune  response  at  sites  distal  from  islets  or  whether 
TNFot is mediating a local effect and playing a direct role 
in pathology of IDDM. We therefore generated transgenic 
mice directly in NOD mice by injection of the RIP-TNFci 
construct  that  we  have  successfully  used  previously  in  a 
non-autoimmune predisposed strain. After initial character- 
ization, we have studied these mice for the development of 
autoimmune diabetes.  We show here that the RIP-TNFot 
transgene  prevents  the  development  of diabetes  in  NOD 
mice and that TNFot itself is not required to be present to 
prevent  the  destruction  of islets  by  autoreactive  T  cells. 
Rather,  protection  is  mediated  by  intervention  at  earlier 
steps  in  the  development  of anti-islet  specific  autoimmu- 
Table 4.  Transfer  of Diabetes by Adoptive Transfer of Diabetogenic CD8 +  Cloned T Cells into Non-irradiated Recipients 
Inodence of diabetes  (weeks post-transfer) 
Source of CeUs  Recipients  5  6  7  8  9  10  11  12  13  14  15  20 
G9-C8  RIP-TNF~  3/5  3/5  3/5  3/5  3/5  3/5  3/5  3/5  3/5  4/5 
G9-C8  NOD  4/5  4/5  4/5  4/5  4/5  4/5  4/5  4/5  4/5  5/5 
4/5  4/5 
6 ×  10  6 diabetogenic cloned CD8+ T cells (G9-C8) were transferred intravenously to RIP-TNFo~ transgenic mace. Diabetes were momtoried by 
urine glucose analysis at weekly intervals. 
1971  Grewal et al. nity and not at the final effector phase. Our data are consis- 
tent with  those  of McDevitt  and  colleagues  (28,  30),  who 
have  shown  that  administration  of TNFcx  to  adult  NOD 
mice  leads  to  protection  of  diabetes.  Our  RIP-TNFoL 
transgenic mice fail to express TNFo~ in the neonatal peri- 
ods where  TNFci exacerbates disease and only start to ex- 
press TNFcx as adults  (7 wk) at which time we also start to 
see infiltration in islets. 
There  are a number of possible explanations  for the ab- 
sence of diabetes in the 1LIP-TNFo~ transgenic NOD  mice. 
First, local expression of TNFci may inhibit the homing of 
autoreactive  cells  to  the  pancreatic  islets;  second,  TNF0~ 
may not prevent the migration of autoreactive cells to islets 
but rather inhibit their ability to initiate or sustain islet spe- 
cific destructive response; third,  auto-reactive cells may fail 
to  develop  in  the  RIP-TNFo~  transgenic  mice;  fourth, 
TNFo~ may alter the properties of islets and make them re- 
sistant  for  destructive  attack  by  autoreactive  cells;  fifth, 
TNFcx  may down  regulate  expression  of autoantigens  on 
islets required for the recognition for successful destructive 
response; finally, expression of TNFci under the control of 
the RIP might lead to general suppression  of the  immune 
system or may directly  alter  the  regulatory  mechanism  of 
the immune system. 
Our  data  presented  here  provide  evidence  to  rule  out 
several of the  possibilities mentioned  above; they also fur- 
ther provide evidence  for the mechanism whereby TNFci 
inhibits development of diabetes.  The lack of development 
of diabetes in 1LIP-TNFci transgenic mice is not due to in- 
hibition  of the  migration  of leukocytes  to  the  islets,  since 
massive islet infiltration is seen in these mice, which is even 
more  dramatic  than  in  the  control  non-transgenic  NOD 
mice.  Moreover,  infiltrating  cells include  CD4,  CD8,  and 
B220 positive cells, and the cellularity of this infiltrate is not 
different  from  the  typical  insulitis  in  control  NOD  mice 
(27).  Despite  massive  infiltration,  immunohistochemistry 
indicates normal insulin levels and a lack of destruction  of 
[3 cells in 1LIP-TNFo~ transgenic mice. These observations 
suggested that infiltrating cells in islets of RIP-TNF(~ mice 
were unable  to initiate  or sustain  an autoimmune  destruc- 
tive response. 
Local expression  of TNFo~ in islets does  not lead to the 
general  suppression  of immune  responses,  since  in  vitro 
proliferative responses of T  cells from R.IP-TNFot are com- 
parable  to  those  of NOD  mice.  In  contrast,  whereas  re- 
sponses to KLH are normal in RIP-TNFo~ transgenic mice, 
specific autoimmune responses to the [3 cell autoantigen GAD 
and autoantigens  contained in islet extracts were inhibited. 
RIP-TNFot  transgenic  mice showed  reduced  immune  re- 
sponses  to  islet auto-antigens  since  the  antibody  response, 
spleen cell proliferation and cytokine production  to a pep- 
tide fragment of GAD is substantially reduced in these ani- 
reals along with lack of response to islet extracts.  GADp524- 
543,  GAD65,  and islet extracts  have been  used previously 
to  measure  autoantigen  specific  responses  of non-diabetes 
prone mice such as Balb/c, B10.GD,  FI(NOD  ×  Balb/c), 
and  other inbred  strains,  and little  to no response to these 
antigens was discovered when compared to the NOD  strain 
(32, 36). Also, GAD reactivity has been only shown to cor- 
relate with insulitis in NOD  mice. Thus, our result suggests 
that TNFo~ abrogates, at least in part, the anti-islet immune 
response. 
To  determine  if local  expression  of TNFot  conferred  a 
long-term protective effect by altering the development of 
autoaggressive cells, we adoptively transferred lymphocytes 
from  age  matched  diabetic  NOD,  non-diabetic  NOD  or 
1LIP-TNFci  transgenic  NOD  mice  to  recipient  NOD- 
SCID mice. Spleen cells from diabetic NOD  mice induced 
diabetes in NOD-SCID  mice rapidly, ~3  wk after transfer. 
However, spleen cells from age matched 1LIP-TNFci trans- 
genic mice did not induce  diabetes in these animals. These 
results  indicate  that  sensitized  autoreactive  lymphocytes 
with  the  potential  to  cause  diabetes  were  absent  in  RIP- 
TNFc~ transgenic  mice,  suggesting that local expression  of 
TNFoL prevents the development ofautoreactive cells. 
These studies provide a potential  explanation  of the fas- 
cinating results of McDevitt's group  (28).  Our data suggest 
first that the TNFc~ mechanism is mediated by local events 
in the islets of Langerhans since PdP-TNFo~ transgenic mice 
do  not  have detectable  levels of systemic TNFci.  We  fur- 
ther  show  that  the  effect of TNFcx  on  the  inhibition  of 
development  of disease is a long-lasting effect on the lym- 
phocytes,  rather  than  a  short-term  inhibition  of effector 
function,  since  transfer  of spleen  cells  from  TNFci  trans- 
genic mice to NOD-SCID  recipients does not provoke di- 
abetes.  Indeed  there  is  no  apparent  inhibition  of effector 
cell function  since active effector cells can transfer diabetes 
to RIP-TNFci NOD  mice (see below). 
The possibility that a regulatory cell population  controls 
the  function  of autoreactive  cells present  in  the  spleen  of 
RIP-TNFo~ transgenic mice is unlikely but cannot be con- 
clusively ruled out by our studies. A more detailed study of 
the  kinetics  of adoptively  transferred  mixtures  of splenic 
cells  from  diabetic  mice  and  splenic  cells  obtained  from 
RIP-TNFo~  mice  to  NOD-SCID  recipients,  using  differ- 
ent ratios and perhaps different subsets ofT  cells is required 
before  making  definitive  conclusions.  We  considered  the 
possibility that the protective effect mediated by TNFol in 
RIP-TNFo~ transgenic  mice might require  the  continuous 
presence  of TNFcx,  for  example,  to  inhibit  the  action  of 
autoaggressive  T  cells.  To  test  this  possibility,  we  adop- 
tively transferred diabetic NOD  splenic cells or cloned dia- 
betogenic  CD8  T  cells to irradiated  NOD  or RIP-TNFcx 
transgenic  mice  recipients,  and  cloned  CD8  T  cells  were 
also adoptively transferred to non-irradiated recipients.  Our 
data indicated that local expression of TNFci does not pro- 
tect against effector cells which are already primed in vivo. 
Taken together,  therefore,  our results show that local pro- 
duction of TNFci in the islets of Langerhans  alters the im- 
mune response to this tissue, thereby preventing the devel- 
opment  of disease.  The  protective  effect  of TNFci,  does 
not appear to require the presence of this cytokine; instead 
this cytokine confers a long-term protective effect by alter- 
ing the autoaggresslve potential of cells from these animals. 
Adoptive transfer experiments suggest a role for TNFci sig- 
nificantly earlier than the delivery of effector function. 
1972  Prevention of Diabetes by Transgene Encoded TNFo~ in Islets The dramatic results that we have seen with TNFIx con- 
firm our recent observations using a  second proinflamma- 
tory cytokine IL-6 (37). Transgenic NOD  mice expressing 
IL-6, under the control of the RIP, also show reduction in 
the  frequency  and  rate  with  which  they develop  IDDM. 
The effect of TNFe¢ is, however, much more pronounced 
than  the  approximately  two-  to  threefold  effect  seen  in 
1KIP-IL-6 transgenic mice  (37).  An inflammatory infiltrate 
is induced in both IL-6 and TNF0¢ transgene mice, but in 
contrast to TNFcx, the inflammatory infiltrate in IL-6 trans- 
gene is found on the NOD  genetic background, but not on 
the  diabetes resistant C57BL/6  background.  Nonetheless, 
these results support the  concept that a  lymphocytic infil- 
trate mediated by these inflammatory cytokines might play 
a protective role. We would like to propose that these cy- 
tokines recruit cells to the aslets, where they encounter islet 
auto-antigens expressed at  enhanced  levels because  of the 
effects of the cytokines. Since islets do not express costimu- 
latory molecules, this encounter between lymphocytes and 
islet cells expressing MHC-peptide, might receive stimula- 
tion only through the antigenic receptor which, under cer- 
tain  circumstances,  has been  shown  to  mediate  anergy in 
vitro; in other cases, such  encounters have been suggested 
to cause apoptosis of T  cells, perhaps mediated by the stim- 
ulation oflFNc~ production (38). An alternative hypothesis 
must be considered, however, and that is that the cytokines 
TNFot and IL-6 have some direct additional protective ef- 
fects, for example, either on the islets or on the infiltrating 
cells.  Further  experiments  using  mice  doubly  transgenic 
mice for TNFci and a diabetogenic TCR  are in progress to 
resolve these issues. 
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